A Contra Capture Protein Array Platform for Studying Post-translationally Modified (PTM) Auto-antigenomes*

Aberrant modifications of proteins occur during disease development and elicit disease-specific antibody responses. We have developed a protein array platform that enables the modification of many proteins in parallel and assesses their immunogenicity without the need to express, purify, and modify proteins individually. We used anticitrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA) as a model modification and profiled antibody responses to ∼190 citrullinated proteins in 20 RA patients. We observed unique antibody reactivity patterns in both clinical anticyclic citrullinated peptide assay positive (CCP+) and CCP- RA patients. At individual antigen levels, we detected antibodies against known citrullinated autoantigens and discovered and validated five novel antibodies against specific citrullinated antigens (osteopontin (SPP1), flap endonuclease (FEN1), insulin like growth factor binding protein 6 (IGFBP6), insulin like growth factor I (IGF1) and stanniocalcin-2 (STC2)) in RA patients. We also demonstrated the utility of our innovative array platform in the identification of immune-dominant epitope(s) for citrullinated antigens. We believe our platform will promote the study of post-translationally modified antigens at a breadth that has not been achieved before, by both identifying novel autoantigens and investigating their roles in disease development. The developed platforms can potentially be used to study many autoimmune disease-relevant modifications and their immunogenicity.

[1]  G. Szücs,et al.  Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis: As Good as it Gets? , 2008, Clinical reviews in allergy & immunology.

[2]  Göran Hallmans,et al.  Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis , 2011, Arthritis research & therapy.

[3]  J. Taylor‐Papadimitriou,et al.  Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. , 2007, Glycobiology.

[4]  K. Deane,et al.  Antibodies to Citrullinated Protein Antigens (ACPAs): Clinical and Pathophysiologic Significance , 2011, Current rheumatology reports.

[5]  J. Taylor‐Papadimitriou,et al.  MUC1 and cancer. , 1999, Biochimica et biophysica acta.

[6]  L. Klareskog,et al.  Targeting of anti-citrullinated protein/peptide antibodies in rheumatoid arthritis using peptides mimicking endogenously citrullinated fibrinogen antigens , 2015, Arthritis Research & Therapy.

[7]  R. Tibshirani,et al.  Autoantibody Epitope Spreading in the Pre-Clinical Phase Predicts Progression to Rheumatoid Arthritis , 2012, PloS one.

[8]  Michael J Taussig,et al.  Printing protein arrays from DNA arrays , 2008, Nature Methods.

[9]  Hans-Jürgen Thiesen,et al.  Mass spectrometric proteome analyses of synovial fluids and plasmas from patients suffering from rheumatoid arthritis and comparison to reactive arthritis or osteoarthritis , 2002, Electrophoresis.

[10]  R Apweiler,et al.  On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. , 1999, Biochimica et biophysica acta.

[11]  D. Deforce,et al.  The relevance of citrullinated vimentin in the production of antibodies against citrullinated proteins and the pathogenesis of rheumatoid arthritis , 2011, Rheumatology.

[12]  D. Gladman,et al.  Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis. , 2006, The Journal of rheumatology.

[13]  C. Alessandri,et al.  Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement , 2004, Annals of the rheumatic diseases.

[14]  S. Schreiber,et al.  Printing proteins as microarrays for high-throughput function determination. , 2000, Science.

[15]  H. Amital,et al.  Anti-citrullinated peptide antibodies is more than an accurate tool for diagnosis of rheumatoid arthritis. , 2013, The Israel Medical Association journal : IMAJ.

[16]  G. Wallstrom,et al.  Immunoproteomic Profiling of Antiviral Antibodies in New-Onset Type 1 Diabetes Using Protein Arrays , 2015, Diabetes.

[17]  M. V. van Boekel,et al.  Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value , 2001, Arthritis research.

[18]  Zhongli Li,et al.  Proteomic analysis of synovial fluid: insight into the pathogenesis of knee osteoarthritis , 2013, International Orthopaedics.

[19]  E. Gravallese.  Osteopontin: a bridge between bone and the immune system. , 2003, The Journal of clinical investigation.

[20]  W. Robinson,et al.  Epitope spreading to citrullinated antigens in mouse models of autoimmune arthritis and demyelination , 2008, Arthritis research & therapy.

[21]  S. Pennington,et al.  Biomarkers of Inflammatory Arthritis and Proteomics , 2013 .

[22]  E. Girbal-Neuhauser,et al.  The Major Synovial Targets of the Rheumatoid Arthritis-Specific Antifilaggrin Autoantibodies Are Deiminated Forms of the α- and β-Chains of Fibrin1 , 2001, The Journal of Immunology.

[23]  S. Anderton.  Post-translational modifications of self antigens: implications for autoimmunity. , 2004, Current opinion in immunology.

[24]  K. Yudoh,et al.  Identification of novel citrullinated autoantigens of synovium in rheumatoid arthritis using a proteomic approach , 2006, Arthritis research & therapy.

[25]  W. Ens,et al.  The identification and characterization of a novel protein, c19orf10, in the synovium , 2007, Arthritis research & therapy.

[26]  Bonnie Bruce,et al.  Antigen microarray profiling of autoantibodies in rheumatoid arthritis. , 2005, Arthritis and rheumatism.

[27]  K. Clauser,et al.  Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[28]  T. Uchida,et al.  Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid. , 2002, Journal of proteome research.

[29]  R. Lührmann,et al.  The C-terminal RG Dipeptide Repeats of the Spliceosomal Sm Proteins D1 and D3 Contain Symmetrical Dimethylarginines, Which Form a Major B-cell Epitope for Anti-Sm Autoantibodies* , 2000, The Journal of Biological Chemistry.

[30]  H. Wandall,et al.  Probing polypeptide GalNAc-transferase isoform substrate specificities by in vitro analysis. , 2015, Glycobiology.

[31]  R. Wait,et al.  Identification of citrullinated α-enolase as a candidate autoantigen in rheumatoid arthritis , 2005, Arthritis research & therapy.

[32]  Mary F. Lopez,et al.  Proteomic analysis of synovial fluid from the osteoarthritic knee: comparison with transcriptome analyses of joint tissues. , 2013, Arthritis and rheumatism.

[33]  Manuel Fuentes,et al.  Nanotechniques in proteomics: protein microarrays and novel detection platforms. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[34]  J. C. Love,et al.  Screening individual hybridomas by microengraving to discover monoclonal antibodies , 2009, Nature Protocols.

[35]  D. Schuppan,et al.  Identification of tissue transglutaminase as the autoantigen of celiac disease , 1997, Nature Medicine.

[36]  M. Malaise,et al.  Comparison of second- and third-generation anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[37]  H. Sayles,et al.  Identification of an immunodominant peptide from citrullinated tenascin-C as a major target for autoantibodies in rheumatoid arthritis , 2015, Annals of the Rheumatic Diseases.

[38]  S. Pennington,et al.  Arrays for protein expression profiling: Towards a viable alternative to two‐dimensional gel electrophoresis? , 2001, Proteomics.

[39]  M. Ahlmén,et al.  Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP) , 2004, Annals of the rheumatic diseases.

[40]  P. Migliorini,et al.  Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[41]  David C Wilson,et al.  Synovial fluid proteins differentiate between the subtypes of juvenile idiopathic arthritis. , 2010, Arthritis and rheumatism.

[42]  M. Gerstein,et al.  Global Analysis of Protein Activities Using Proteome Chips , 2001, Science.

[43]  W. Robinson,et al.  Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. , 2006, The Journal of clinical investigation.

[44]  Thomas P. Clausen,et al.  A high-throughput O-glycopeptide discovery platform for seromic profiling. , 2010, Journal of proteome research.

[45]  Xiaobo Yu,et al.  Antiviral antibody profiling by high‐density protein arrays , 2015, Proteomics.

[46]  P. Tak,et al.  Citrullinated proteins in rheumatoid arthritis: crucial...but not sufficient! , 2006, Arthritis and rheumatism.

[47]  E. Lapointe,et al.  Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin , 2004, Arthritis research & therapy.

[48]  S. Heath,et al.  Myelin Basic Protein as a Novel Genetic Risk Factor in Rheumatoid Arthritis—A Genome-Wide Study Combined with Immunological Analyses , 2011, PloS one.

[49]  Peter Wiktor,et al.  High density diffusion-free nanowell arrays. , 2012, Journal of proteome research.

[50]  D. Arkfeld,et al.  Targeted Synovial Fluid Proteomics for Biomarker Discovery in Rheumatoid Arthritis , 2009, Clinical Proteomics.

[51]  Alejandro Merino,et al.  Erratum to: Emerging technology of in situ cell free expression protein microarrays , 2012, Protein & Cell.

[52]  B. Dijkmans,et al.  Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis , 2005, Annals of the rheumatic diseases.

[53]  Yanhui Hu,et al.  Next generation high density self assembling functional protein arrays , 2008, Nature Methods.

[54]  S. Poulsen,et al.  Seromic profiling of colorectal cancer patients with novel glycopeptide microarray , 2011, International journal of cancer.

[55]  Lawrence A Tabak,et al.  Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. , 2012, Glycobiology.

[56]  T. Kano,et al.  A retrospective study of the fluctuation in serum levels of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. , 2005, Clinical and experimental rheumatology.

[57]  A. Chauhan,et al.  Proteomic analysis of circulating immune complexes in juvenile idiopathic arthritis reveals disease‐associated proteins , 2009, Proteomics. Clinical applications.

[58]  J. LaBaer,et al.  Recombinational Cloning , 2006, Current protocols in molecular biology.

[59]  L. Alfredsson,et al.  Immunity to citrullinated proteins in rheumatoid arthritis. , 2008, Annual review of immunology.

[60]  P. Brown,et al.  Autoantigen microarrays for multiplex characterization of autoantibody responses , 2002, Nature Medicine.

[61]  Jinxiang Han,et al.  Identification of Proteins with Increased Expression in Rheumatoid Arthritis Synovial Tissues , 2009, The Journal of Rheumatology.

[62]  G. Pruijn,et al.  All you wanted to know about anti-CCP but were afraid to ask. , 2010, Autoimmunity reviews.

[63]  Henrik Clausen,et al.  Mucin-type O-glycosylation and its potential use in drug and vaccine development. , 2008, Biochimica et biophysica acta.

[64]  H. Hirano,et al.  Deimination of arginine residues in nucleophosmin/B23 and histones in HL-60 granulocytes. , 2002, Biochemical and biophysical research communications.

[65]  Peter J Millett,et al.  High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis , 2007, Arthritis research & therapy.

[66]  L. Alfredsson,et al.  Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile , 2012, Annals of the rheumatic diseases.

[67]  G. Pruijn.  Citrullination and Carbamylation in the Pathophysiology of Rheumatoid Arthritis , 2015, Front. Immunol..

[68]  M. Ziman,et al.  Serologic Autoantibodies as Diagnostic Cancer Biomarkers—A Review , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[69]  A. Gammerman,et al.  Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer , 2013, British Journal of Cancer.

[70]  K. Bunai,et al.  Effectiveness and limitation of two-dimensional gel electrophoresis in bacterial membrane protein proteomics and perspectives. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[71]  M. Taussig,et al.  Cell free expression put on the spot: advances in repeatable protein arraying from DNA (DAPA). , 2011, New biotechnology.

[72]  E. Lapointe,et al.  Insights into rheumatoid arthritis derived from the Sa immune system , 2000, Arthritis research.

[73]  Yanhui Hu,et al.  Tracking humoral responses using self assembling protein microarrays , 2008, Proteomics. Clinical applications.

[74]  M. Hudson,et al.  A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis , 2007, Clinical Rheumatology.

[75]  W. V. van Venrooij,et al.  Anti‐CCP Antibody, a Marker for the Early Detection of Rheumatoid Arthritis , 2008, Annals of the New York Academy of Sciences.